BLFS BioLife Solutions, Inc. Full Business Value

BioLife (BLFS) - corporate logo

BioLife Solutions, Inc. (BLFS) is optimizing costs by outsourcing component manufacturing and logistics to external partners. The business seeks dominance in the biopreservation segment by integrating proprietary CryoStor media into the protocols of emerging biotech projects. The price trend on GURU.Markets, where the Enterprise Value stands at 1822.12, confirms the impact of growing demand for gene therapy consumables, while the market has already priced in the effect of non-core asset divestitures.

BLFS BioLife: Enterprise Value in the range 11/23/2025 - 10/18/2026
Original product of BioLife Solutions, Inc.

Enterprise Value determines the total value of a business, accounting for all forms of capital. By analyzing the enterprise value as of the current date, an investor sees the actual acquisition price of the asset. The metric sums market capitalization and debt, subtracting cash and cash equivalents. This calculation is sensitive to debt load and liquidity. For BioLife Solutions, Inc. (BLFS), this figure reflects the market value of the infrastructure supporting the expansion of biopreservation systems within the gene therapy sector.

Competing companies

Total Company Value Tempus AI TEM|Enterprise Value Qiagen Group|IONS: Full Business Value|Repligen Corporation - Total Company Value|aviditybiosciences.com (RNA) - Company Buyout Price|Enterprise Value CRISPR Therapeutics (CRSP)|Business Value WGS|Total Company Value Ultragenyx Pharma RARE|Business Value Beam Tx (BEAM)|Enterprise Value SRPT (Sarepta Therapeutics, Inc.)|Enterprise Value twistbioscience.com TWST|TXG - Enterprise Value|NTLA - Total Company Value|Stoke - Enterprise Value|WVE (Wave Pharma) - Company Buyout Price|Total Company Value MAZE (Maze Therapeutics Inc)|Total Enterprise Value SION|Total Company Value Prime Medicine (PRME)|Total Company Value Taysha Gene Therapies Inc (TSHA)|Enterprise Value QURE|Company Buyout Price MeiraGTx Corp MGTX|Enterprise Value REGENXBIO Inc.|SLDB - Full Business Value|Enterprise Value OCGN|Total Enterprise Value Pacific Biosciences of California, Inc.|BNTC - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash DSGN|RCKT (Rocket Pharmaceuticals) - Total Company Value|Company Buyout Price FDMT (4dmoleculartherapeutics.com)|LXEO: Total Company Value|Korro Bio Inc. - Total Enterprise Value|EDIT - Total Company Value|Silence Therapeutics Corp (SLN) - Total Company Value|PRQR: Real Price to Acquire Entire Company|Enterprise Value Codexis|Sangamo Therapeutics, Inc. (SGMO) - Real Price to Acquire Entire Company|Aggregate Business Value Nautilus Biotechnology Inc|MGX (Metagenomi, Inc) - Enterprise Value|Company Buyout Price DTIL (precisionbiosciences.com)|GBIO: Total Company Value|boundlessbio.com - Total Enterprise Value|Exicure Corp (XCUR) - Total Company Value|IMNN: Business Value|phiopharma.com - Total Company Value|Company Buyout Price Mustang Bio|RNAZ - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Bionano|APDN (Applied DNA Sciences, Inc.) - Enterprise Value|Company Buyout Price BLUE (bluebird bio Inc.)|IPA - Total Company Value|Business Value Omega Therapeutics Corp OMGA|OMIC: Enterprise Value|regulusrx.com (RGLS) - Real Price to Acquire Entire Company|Syros Pharmaceuticals, Inc. - Real Price to Acquire Entire Company|Telesis Bio Inc. (TBIO) - Company Buyout Price|Enterprise Value TRACON|Total Company Value UBX